SUMO1 and pancreatic adenocarcinoma: Further investigation revealed that the coexpression of SUMO family members with M6A methylation regulators and a variety of oncogenes, their activating roles in a variety of oncogenic pathways, their close association with TP53 mutation status, and the negative regulatory effect of SUMO1/2 on PAAD immunity are potential mechanisms mediating the role of SUMO family members in promoting PAAD.